window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

systemic lupus erythematosus

  • Clinical & Regulatory,Drug Discovery & Development,Research & Development,Therapeutic Areas

    NEJM study provides first clinical evidence for NET-degrading therapy in lupus

    A study published in The New England Journal of Medicine [...]

    July 17, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Merck wins FDA Breakthrough Therapy designation for lupus drug enpatoran

    Merck has received FDA Breakthrough Therapy designation for enpatoran, an [...]

    July 9, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    AstraZeneca highlights long-term remission and steroid-sparing data for Saphnelo at EULAR 2026

    AstraZeneca is presenting a broad package of new clinical and [...]

    June 9, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Saphnelo self-administration recommended for EU approval for systemic lupus

    AstraZeneca has received a positive recommendation from the Committee for [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Saphnelo self-administration Phase 3 trial meets primary endpoint in systemic lupus erythematosus

    AstraZeneca has reported positive interim results from the Phase 3 [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
  • Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial
    Categories: Clinical & Regulatory, Medical devices, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top